Retacrit Injection, Solution
Product Images NDC 0069-1318

Product Visual Gallery

This gallery contains 33 technical images submitted to the FDA as part of the official labeling for Retacrit (NDC 0069-1318). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Logo (Retacrit 01)

FDA Label Image

Logo (Retacrit 02)

FDA Label Image

Figure 1 (Retacrit 03)

FDA Label Image

Figure 2 (Retacrit 04)

FDA Label Image

Figure 3 (Retacrit 05)

FDA Label Image

Figure 4 (Retacrit 06)

FDA Label Image

Figure 5 (Retacrit 07)

FDA Label Image

Figure 6 (Retacrit 08)

FDA Label Image

Figure 7 (Retacrit 09)

FDA Label Image

Figure 8 (Retacrit 10)

FDA Label Image

Figure 9 (Retacrit 11)

FDA Label Image

Figure 10 (Retacrit 12)

FDA Label Image

Figure 11 (Retacrit 13)

FDA Label Image

Figure 12 (Retacrit 14)

FDA Label Image

Figure 13 (Retacrit 15)

FDA Label Image

Figure 14 (Retacrit 16)

FDA Label Image

Figure 15 (Retacrit 17)

FDA Label Image

Figure 16 (Retacrit 18)

FDA Label Image

Logo (Retacrit 19)

FDA Label Image

Principal Display Panel (2,000 Units/mL Vial Label)

Retacrit® is a medication available in a 2,000 Units/mL single-dose vial, containing epoetin alfa. It is prescribed by healthcare professionals and distributed by Pfizer Labs in New York, NY. The medication should be stored at 2°C to 8°C. Dosage information is available in the prescribing information. The medication is manufactured by Hospira, Inc., a Pfizer Company, and operations are licensed within the USA with License No. 1974.*

FDA Label Image

Principal Display Panel (2,000 Units/mL Vial Carton)

Retacrit® is a solution that contains Epoetin Alfa-epbx recombinant for intravenous or subcutaneous use. It is available in a single-dose vial, and any unused portion should be discarded. The solution is a buffered solution of calcium chloride dihydrate, sodium chloride, and other additives. The vial must be stored refrigerated at 2°C to 8°C. Retacrit® is distributed by Pfizer Labs and should always be dispensed with enclosed medication instructions.*

FDA Label Image

Principal Display Panel (3,000 Units/mL Vial Label)

Retacrit is a medication produced by Hospira, now owned by Pfizer. It is only available through prescription and contains Epoetin Alfa-epbx. The concentration is 3,000 Units/mL and comes in a single-dose vial. It is distributed by Pfizer Labs, which is a division of Pfizer Inc. The medication is used in the field of oncology.*

FDA Label Image

Principal Display Panel (3,000 Units/mL Vial Carton)

Retacrit® is a medication that comes in a single-dose vial containing 1053000 Units of Epoetin Alfa-epbx intended for intravenous or subcutaneous use only. It also contains glycine, isoleucine, leucine, and other components. The medication should not be frozen or shaken, and any unused portion must be discarded. The solution is sterile and does not contain any preservatives. The medication is distributed by Pfizer Labs and is manufactured in Lake Forest, IL, USA.*

FDA Label Image

Principal Display Panel (4,000 Units/mL Vial Label)

NDC 0069-1307-01 is a prescription drug called Retacrit. It contains Epoetin Alfa-epbx and is manufactured by Hospira, Inc, a Pfizer company. The drug is a recombinant protein used to treat anemia. The dosage information can be found on the prescription label. The drug is available in a single-dose vial containing 4,000 Units/mL. It is distributed by Pfizer Labs.*

FDA Label Image

Principal Display Panel (4,000 Units/mL Vial Carton)

Retacrit® is a recombinant epoetin alfa-epbx solution used for Subcutaneous or Intravenous use. The medication comes in a Single-dose vial and should be refrigerated but not frozen or shaken. It is always recommended to dispense the enclosed medication guide to each patient. Please note that the text provided contains errors and some information is missing.*

FDA Label Image

Principal Display Panel (10,000 Units/mL Vial Label)

Retacrit is a medication that requires a prescription and should be stored at a temperature between 2 and 8 degrees Celsius. It is a Pfizer Inc. product that contains recombinant epoetin alfa and is manufactured by Hospira, Inc. The medication is distributed by Pfizer Labs in the United States under license number 1974. The provided reference number is PAA143574.*

FDA Label Image

Principal Display Panel (10,000 Units/mL Vial Carton)

Retacrit® is a 10,000 Units/mL recombinant solution of epoetin alfa-epbx that can be used for intravenous or subcutaneous delivery. It is a single-dose vial that does not contain any preservatives. Individuals with phenylketonuria should be aware that Retacrit® contains phenylalanine. The medication should be discarded if not used in its entirety, and it should not be shaken before use. The prescribing information should be consulted for proper usage. The solution is manufactured by Hospira, Inc., a Pfizer Company, and distributed by Pfizer Labs.*

FDA Label Image

Principal Display Panel (40,000 Units/mL Vial Label)

This is a medication used for oncology in a single-dose vial with a concentration of 40,000 units per milliliter. The dosage information can be found in the prescribing information. It should be stored at 2°C to 8°C and manufactured by Hospira, a Pfizer company. The distribution of this medication is handled by Pfizer Labs in New York. The lot number and expiration date are provided, but there is no information about what the medication actually does or what it is used for.*

FDA Label Image

Principal Display Panel (40,000 Units/mL Vial Carton)

This is a description of a drug named "Retacrit®", which comes in single-dose vials containing 1 ml of recombinant Epoetin Alfa-epb. The drug is for subcutaneous use only and must be discarded after a single-use. The package includes an enclosed navigation guide to each patient. The text also includes some cautionary notes, a warning for Phenylketonurics and the manufacturing details.*

FDA Label Image

Principal Display Panel (20,000 Units/mL Vial Label)

This is a label of medication produced by Hospira, Inc. which is a subsidiary of Pfizer Inc. The medication is prescribed for Sos (unknown medical condition) and contains important information. The manufacturer's address is located in Lake Forest, IL, and it holds US License No. 1974. The distribution of this medication is by Pfizer Labs, a division of Pfizer Inc located in New York, NY. The number PAA15870 may be a batch number or a specific identifier for this medication.*

FDA Label Image

Principal Display Panel (20,000 Units/mL Vial Carton)

FDA Label Image

Principal Display Panel (20,000 Units/2 mL Vial Label)

FDA Label Image

Principal Display Panel (20,000 Units/2 mL Vial Carton)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.